HIGH BIOAVAILABILITY: Formulated as "Reduced" L-Glutathione, the stable form that is more effectively utilized by the body compared to standard glutathione
A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and/or chronic kidney disease
Dosage can be adjusted based on individual response and tolerance
The study included adults aged 1870 with moderately active UC (MS 5-9), MES 2, RBS 1, and disease extending 20cm from anal verge, while excluding those with CD, infections, or recent surgeries, with concomitant stable mesalamine and steroids permitted
KEY OBSERVATIONS Cancellation is straightforward
Both drugs lower blood sugar and A1c levels, improve insulin sensitivity, decrease insulin resistance, and may lead to weight loss